Lazard Asset Management LLC Halozyme Therapeutics, Inc. Transaction History

Lazard Asset Management LLC

$68.3 Billion
Q3 2024

A detailed history of Lazard Asset Management LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 217,655 shares of HALO stock, worth $9.94 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

217,655

Previous 452,556 51.91%

Holding current value

$9.94 Million

Previous $23.7 Million 47.45%

% of portfolio

0.02%

Previous 0.03%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $12.1 Million - $15.1 Million	-234,901 Reduced 51.91%	217,655 $12.5 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $13.4 Million - $18.5 Million	-353,419 Reduced 43.85%	452,556 $23.7 Million
Q1 2024 May 14, 2024	SELL	$33.68 - $41.95 $3.08 Million - $3.83 Million	-91,372 Reduced 10.18%	805,975 $32.8 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $1.23 Million - $1.55 Million	36,873 Added 4.29%	897,347 $33.2 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $12.3 Million - $14.9 Million	-338,193 Reduced 28.21%	860,474 $32.9 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $15.1 Million - $19.3 Million	499,063 Added 71.34%	1,198,667 $43.2 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $8.35 Million - $14.2 Million	254,063 Added 57.02%	699,604 $26.7 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $1.68 Million - $2.49 Million	-41,902 Reduced 8.6%	445,541 $25.4 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $18.5 Million - $24.9 Million	481,440 Added 8019.99%	487,443 $19.3 Million
Q2 2022 Aug 09, 2022	BUY	$37.35 - $48.3 $217,003 - $280,623	5,810 Added 3010.36%	6,003 $264,000
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $95,398 - $122,523	-2,984 Reduced 93.93%	193 $7,000
Q4 2021 Feb 09, 2022	BUY	$31.82 - $40.75 $20,332 - $26,039	639 Added 25.18%	3,177 $127,000
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $6,232 - $7,520	-162 Reduced 6.0%	2,538 $103,000
Q2 2021 Aug 12, 2021	BUY	$38.84 - $51.31 $7,690 - $10,159	198 Added 7.91%	2,700 $122,000
Q1 2021 May 14, 2021	BUY	$39.51 - $51.45 $18,964 - $24,696	480 Added 23.74%	2,502 $104,000
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $3.83 Million - $4.41 Million	-148,718 Reduced 98.66%	2,022 $53,000
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $2.45 Million - $4.04 Million	150,740 New	150,740 $4.04 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $35,055 - $55,055	-2,522 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $30,725 - $40,192	2,058 Added 443.53%	2,522 $44,000
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $7,052 - $8,208	464 New	464 $7,000

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.36B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account

Lazard Asset Management LLC Halozyme Therapeutics, Inc. Transaction History